Racial Variation in the Uptake of Onco type DX Testing for Early-Stage Breast Cancer by Roberts, Megan C. et al.
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
Megan C. Roberts, Morris Weinberger,
Stacie B. Dusetzina, Katherine E. Reeder-
Hayes, Lisa A. Carey, Melissa A. Troester,
and Stephanie B. Wheeler, University of
North Carolina at Chapel Hill, Chapel Hill;
Morris Weinberger, Durham Veterans
Affairs Medical Center for Health Services
Research; and Michaela A. Dinan, Duke
Clinical Research Institute and Duke
Cancer Institute, Durham, NC.
Published online ahead of print at
www.jco.org on November 23, 2015.
Terms in blue are defined in the glossary,
found at the end of this article and online
at www.jco.org.
Support information appears at the end
of this article.
Authors’ disclosures of potential conflicts
of interest are found in the article online at
www.jco.org. Author contributions are
found at the end of this article.
Corresponding author: Megan C. Roberts,
PhD, University of North Carolina at
Chapel Hill, Department of Health Policy
and Management, Gillings School of
Global Public Health, McGavran-
Greenberg Hall, CB# 7411, Chapel Hill,
NC 27599-7411; e-mail: mclarker@
unc.edu.
© 2015 by American Society of Clinical
Oncology
0732-183X/16/3402w-130w/$20.00
DOI: 10.1200/JCO.2015.63.2489
Racial Variation in the Uptake of Oncotype DX Testing for
Early-Stage Breast Cancer
Megan C. Roberts, Morris Weinberger, Stacie B. Dusetzina, Michaela A. Dinan, Katherine E. Reeder-Hayes,
Lisa A. Carey, Melissa A. Troester, and Stephanie B. Wheeler
A B S T R A C T
Purpose
Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemotherapy decision-
making. ODX has the potential to improve quality of care; however, if not equally accessible across
racial groups, disparities in cancer care quality may persist or worsen.We examined racial disparities
in ODX testing uptake.
Methods
We used data from the Carolina Breast Cancer Study, phase III, a longitudinal, population-based
study of 2,998 North Carolina women who received a diagnosis of breast cancer between 2008 and
2014. Our primary analysis usedmodified Poisson regression to determine the association between
race and whether ODX testing was ordered among two strata: node-negative and node-positive
breast cancer.
Results
A total of 1,468 women with estrogen receptor–positive, human epidermal growth factor receptor-
2–negative, stage I or II breast cancer met inclusion criteria. Black patients had higher-grade and
larger tumors, more comorbidities, younger age at diagnosis, and lower socioeconomic status than
non-black women. Overall, 42% of women had ODX test results in their pathology reports.
Comparedwith thosewho did not receiveODX testing, womenwho receivedODX testing tended to
be younger and have medium tumor size and grade. Our regression analyses indicated no racial
disparities in ODX uptake among node-negative patients. However, racial differenceswere detected
among node-positive patients, with black patients being 46% less likely to receive ODX testing than
non-black women (adjusted relative risk, 0.54; 95% CI, 0.35 to 0.84; P = .006).
Conclusion
We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is
guideline recommended and widely covered by insurers. However, our findings suggest that a
newer, non–guideline-concordant application of ODX testing for node-positive breast cancer was
accessed less by blackwomen than by non-black women, reflectingmore guideline concordant care
among black women.
J Clin Oncol 34:130-138. © 2015 by American Society of Clinical Oncology
INTRODUCTION
This year, an estimated 231,840 womenwill receive a
diagnosis of invasive breast cancer,1 almost 50%with
early-stage, hormone receptor–positive disease.2,3
Among these women, some will benefit from che-
motherapy in addition to endocrine therapy as part
of their adjuvant therapy. Historically, clinicopath-
ologic features such as tumor grade, size, age, and
comorbidities, have driven adjuvant chemotherapy
decision-making.4,5 However, commercially available
genetic technologies, such as Oncotype DX test
(ODX; Genomic Health, Redwood City, CA),
alleviate some uncertainty associatedwith the use of
only clinicopathologic criteria to estimate adjuvant
chemotherapy benefit.
ODX testing became commercially available
in 2004 for the management of early-stage, node-
negative, estrogen receptor–positive (ER+) breast
cancer.6 This 21-tumor gene expression profiling
panel categorizes the disease into low-, inter-
mediate-, or high-risk groups on the basis of the
10-year risk of distant recurrence.7 Women with
130 © 2015 by American Society of Clinical Oncology
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low-risk scores are unlikely to benefit from the addition of che-
motherapy to adjuvant endocrine therapy, whereas women with
high scores derive considerably more benefit.7 Evidence suggests that
providers change adjuvant chemotherapy decision-making in 30%
to 40% of patients in the presence of ODX test results,8-12 reducing
the overuse of adjuvant chemotherapy.5,13 Furthermore, ODX
testing appears to be cost-effective.5,14,15 Level I evidence of che-
motherapy decision-making based on ODX in node-negative, ER+
disease awaits results of the randomized TAILORx trial.16
The first private insurer began covering ODX testing for
women with ER+, human epidermal growth factor receptor 2–
negative (HER22), early-stage breast cancer in 2005.6 Medicare
began covering ODX testing for these patients in 2006.6 Soon
thereafter, medical guidelines began incorporating ODX testing for
adjuvant chemotherapy decision-making for patients with node-
negative breast cancer with ER+, HER22, stage I or II disease with
tumors 0.5 cm or larger.6 Since its initial validation in patients with
node-negative disease, several studies have demonstrated the
prognostic validity of ODX testing for certain subgroups of women
with one to three positive nodes as well.17-19 Investigators in the
ongoing RxPONDER trial will evaluate ODX testing for women
with early-stage, node-positive, ER+ breast cancer.20 Currently,
ODX testing for women with positive lymph nodes is not guideline
recommended or widely covered by insurance providers.
By helping clinicians make individualized, evidence-based
decisions regarding chemotherapy, ODX testing can contribute
to targeted, high-quality care for women with breast cancer.
However, if such technologies are not equally accessible by patients,
it may unintentionally exacerbate existing disparities in breast
cancer care processes and outcomes.21 Because only one third of
patients with guideline-eligible disease (ie, node-negative, ER+
disease in stage I or II) receive ODX testing,22 an understanding of
who is tested is critical for targeting interventions to increase its
use. The few studies in which researchers examined racial dif-
ferences in ODX testing offered mixed evidence.22-25 Of note, these
studies have limited generalizability because they were conducted
in academic settings,22,24 in hospitals within a single urban
setting,22,23 or among only Medicare beneficiaries.26
We sought to extend previous research by examining racial
variation in ODX testing across a diverse patient population.
Furthermore, we sought to disentangle the effect of race on ODX
testing on the basis of lymph node status because clinical guidelines
and insurance coverage vary.
METHODS
Data Source
The Carolina Breast Cancer Study (CBCS phase III) is a population-
based study of women with a diagnosis of breast cancer from across 44
North Carolina counties. Because it oversampled black and young women,
CBCS phase III is particularly well powered to examine racial health
disparities in breast cancer. Between 2008 and 2013, CBCS phase III
investigators enrolled 2,998 women, 20 to 74 years old, with invasive breast
cancer by means of rapid case ascertainment in collaboration with the
North Carolina Cancer Registry. Patients were randomly selected for
recruitment in four strata: black women younger than 50 years, black
women aged 50 years or older, non-black women younger than 50 years,
and non-black women aged 50 years or older. For this study, we used
baseline survey, medical record and pathology report abstraction data. This
research was approved by the University of North Carolina institutional
review board.
Subjects
We included women whose breast cancer was ER+, stage I or II, and
HER22. Patients were excluded if they had multiple tumors
or undetermined tumor grade, size, or progesterone receptor (PR) status
(Fig 1). Missing data about tumor characteristics was rare for black (1.5%)
and non-black (2.1%) women (P = .51). Given our sample sizes, we
estimated that with 80% power and a two-sided a of 0.05, we could detect
18.7% and 37.5% changes in relative risk among women with node-
negative or node-positive disease, respectively.27
Measures
We used the definition of the Institute of Medicine for health dis-
parity: “the difference in treatment or access not justified by the differences
in health status or preferences of the groups.” This definition implies that
race is a social construct and, thus, controls for socioeconomic status (SES)
variables associated with race may mask existing racial disparities.28,29 As
such, SES factors, that is, marital status, education, employment after
diagnosis, family income, and insurance type, were not included in our
primary model with which we estimated the reduced form effect of race on
ODX testing. To examine the residual direct effect of race on ODX testing,
we developed a secondary model that included SES covariates.
N = 2,998 
N = 55
Multiple tumors
N = 2,943 
N = 804
ER Negative
N = 2,139 
N = 353
Stage III to IV
N = 1,786 
N = 279
HER2+
N = 1,507 
N = 16
Undetermined grade
N = 1,491 
n = 23
Missing tumor size or PR Status
N = 1,468 
Fig 1. Composition of sample population with exclusion criteria. ER, estrogen
receptor; HER2+, human epidermal growth factor receptor 2–positive; PR, pro-
gesterone receptor.
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Dependent variable. ODX testing information was abstracted from
pathology reports. Patients without ODX reports in their pathology
records were assumed not to have received the test.
Independent variable. Race, abstracted from the baseline survey, was
patient self-reported. Race was dichotomized as non-black, which included
white, Asian, and other, and as black, irrespective of ethnicity.
Covariates. Covariates included the tumor characteristics (stage, size,
grade, and PR status), treatment (lumpectomy v mastectomy and radia-
tion), and clinical characteristics (comorbidities and age). Age at diagnosis
was dichotomized as younger than 50 years or 50 years or older. From
baseline surveys, we calculated a count of comorbidities from five clinical
categories: heart disease, hypertension, obesity, diabetes, and chronic
obstructive pulmonary disease. Tumor and treatment characteristics were
abstracted from pathology and medical reports, respectively. Tumor stage
and radiation therapy were dropped because of multicollinearity with
tumor size and surgery type, respectively. Endocrine therapy and adjuvant
chemotherapy determined from medical record abstraction were each
dichotomized as ever starting therapy or not. Adjuvant chemotherapy was
defined as chemotherapy that occurred after the first primary surgery, that
is, lumpectomy or mastectomy. Our secondary model also included the
SES variables of marital status, which was married or living as married
versus other; education less than high school, high school, or college and
more; current employment as yes, no, or not reported; annual family
income of less than $15,000, $15,000 to $30,000, $30,000 to $50,000, more
than $50,000, or not reported; and insurance status as insured versus
uninsured.
Analyses
Descriptive statistics were calculated by using population weights. We
compared black and non-black women, as well as those who did and did
not receive ODX testing using weighted linear regression and weighted x2
tests for continuous and binary or categorical variables, respectively. We
also reported ODX uptake over time by node status, using weighted x2
tests. Multivariate analyses were based on a modified Poisson regression
with sandwich error terms, which estimates relative risk consistently and
efficiently with binary outcomes.30,31 Both descriptive and multivariate
analyses addressed complex survey design by means of sample weights and
design effects with the use of Taylor series approximations. We also
accounted for clustering at the provider level. Analyses were conducted by
using STATA (StataCorp, College Station, TX). Because racial differences
may change as new evidence emerges for ODX testing, we conducted an
exploratory analysis to observe qualitative racial differences in ODXuptake
overtime by node status.
Factors that influence ODX testing may vary between women with
lymph node–positive and those with lymph node–negative breast cancer;
therefore, we conducted sensitivity analyses. This uncovered a need to
stratify analyses by lymph node status of N0 versus N1. As a result, we
present six models: unadjusted, primary, and secondary models within
each lymph node stratum.
RESULTS
Characteristics of Patients by Race and ODX Uptake
Overall, non-black women tended to have fewer comorbidities,
older age at diagnosis, and higher SES than black women; they also
had tumors that were PR-positive and smaller and lower grade than
those of black women (Table 1). Fewer black women received ODX
testing than non-black women (33.9% v 43.2%, P = .001). However,
when stratified by node status, this racial difference was present only
among patients with node-positive disease (14.4% v 34.0%, P,.001).
Less than 50% of women who met criteria for ODX testing
had test results in their pathology report. Patients with node-
positive disease were less likely to receive ODX testing than patients
with node-negative disease (30% v 45%, P = .001); however, this
difference diminished over time (Fig 2). ODX testing rates
increased among women with node-positive disease in 2012 to
2013 compared with 2008, whereas they stayed relatively stable
among patients with node-negative disease. Of interest, ODX
testing rates among both subpopulations were similar after 2008
(Fig 2). Exploratory analyses suggested that racial differences in
ODX test uptake were stable over time within each stratum (data
not shown). Patients receiving ODX testing tended to be younger,
to have fewer comorbidities, to have tumors smaller than 2 cm and
tumors of grade II than patients who did not receive the test. Those
receiving ODX testing were also more likely to receive adjuvant
chemotherapy than women who did not; both groups were equally
likely to start endocrine therapy (Table 2).
Race and Other Characteristics Independently
Associated With Receiving the ODX Test
Among patients with node-negative disease, race was not
associated with receiving ODX testing across models (Table 3).
Tumor characteristics were independently associated with ODX
testing; higher tumor grade, PR positivity, and tumor size of 2 to
5 cmwere associated with a greater likelihood of a woman receiving
ODX testing among those with node-negative disease. SES factors
among patients with node-negative disease were not associated
with ODX test performance. Year of diagnosis was not associated
with a patient’s receiving ODX testing among women with node-
negative disease.
Among patients with node-positive disease, black women
were significantly less likely to receive ODX testing than non-black
women (adjusted risk ratio [aRR], = 0.54, 95% CI, 0.35 to 0.84; P =
.006; Table 4). Furthermore, women younger than 50 years with
positive nodes were significantly less likely to receive ODX testing
than women aged 50 years or older (aRR, 0.49; 95% CI, 0.32 to
0.75; P = .001, aRR, 0.52; 95% CI, 0.33 to 0.80; P = .003). Women
were significantly more likely to receive ODX testing in 2012 to
2013 compared with 2008 (aRR, 3.2; 95% CI, 1.15 to 8.76; P = .03,
aRR, 3.1; 95% CI, 1.088 to 8.86; P = .034). These findings were
consistent across models. However, race was not statistically
associated with receiving ODX testing in our secondary model
(aRR, 0.68; 95% CI, 0.39 to 1.19; P = .172).
DISCUSSION
Between 2008 and 2013, less than 50% of women in North
Carolina who were eligible for ODX testing—that is, those with
early-stage, ER+, HER22, node-negative breast cancer—received
ODX testing, and about one third with node-positive breast cancer
received ODX testing. However, uptake of ODX testing increased
over time among patients with node-positive disease. To our
knowledge, our article is the first to describe racial differences in
ODX testing among a diverse subgroup of women with node-
positive disease, a group in whom ODX testing is becoming more
common than before, despite unfavorable clinical guidelines and a
lack of universal insurance coverage.
Overall, black women were more likely to begin adjuvant
chemotherapy than non-black women. This is likely because
132 © 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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black women had larger, higher-grade breast cancers than those
of non-black women, consistent with CBCS phase I and II
findings.32 Among patients with node-negative disease, the rate of
starting adjuvant chemotherapy was higher among those who
received ODX testing than those who did not. Of note, this pattern
was reversed among patients with node-positive disease. Among
womenwith node-negative disease, patients were less likely to receive
ODX testing if they have preferences against adjuvant chemotherapy
Table 1. Population-Weighted Sample Characteristics by Race and Lymph Node Status
Full Sample Node Positive Node Negative
Characteristic Non-Black Black P Non-Black Black P Non-Black Black P
N 859 609 203 180 656 429
Weighted N 3,895 793 828 218 3,067 574
ODX testing
Assay included 43.2 33.9 .001 34 14.4 , .001 45.7 41.4 .23
Recurrence score 17.7 (8.3) 19 (16.2) .17 18.0 (6.4) 19.2 (13.9) .61 17.7 (8.7) 19.0 (16.7) .2
Tumor
Stage I v II 65.9 55.3 , .001 11.6 7 .16 80.6 73.7 .02
Size, cm , .001 .22 .01
, 2 75.5 65.9 54.8 45.5 81 73.7
2-5 22.4 32.3 43.5 53.3 16.8 24.3
. 5 2.1 1.8 1.7 1.2 2.2 2
Grade , .001 .003 .004
1 38.4 27.9 29.5 18.2 40.8 31.6
2 46 47.2 48.8 43.8 45.2 48.5
3 15.6 24.9 21.7 38 13.9 20
PR positive 89.9 80.8 , .001 92.5 80.2 .004 89.2 81 , .001
Treatment
Start ET 90.7 87.1 .06 93.7 88.2 .08 89.8 86.7 .15
Start adjuvant CT 27.5 36.7 , .001 56.6 66.1 .09 19.6 25.5 .03
Radiation therapy 68.1 68 .97 71.3 76.3 .3 67.3 64.9 .49
Lumpectomy* 62.9 61.9 49.4 49.2 .97 66.5 66.7 .13
Clinical
Age at diagnosis, years 57.7 (8.7) 55.5 (16.9) .003 56.0 (9.2) 52.6 (15.0) , .001 58.2 (8.6) 56.6 (17.2) .04
Diagnosis year .49 .41 .49
2008 11.2 10.9 14.8 14.5 10.2 9.6
2009 19.4 19.2 15.7 22.6 20.4 17.9
2010 24.3 23 19.9 19.7 25.5 24.3
2011 23.7 28 26.4 27.3 23 28.3
2012 or 2013 21.4 18.8 23.2 12.2 20.9 20
Comorbidities
Diabetes 11 25.7 , .001 12.5 20.8 .06 10.6 27.6 , .001
COPD 3.6 3.4 .87 3.8 3.2 .77 3.6 3.5 .97
Obesity 11 21.9 , .001 10 19.5 .02 11.3 22.8 , .001
Heart disease 6.7 7.2 .73 7.8 5.5 .43 6.4 7.9 .41
Hypertension 38.9 65.7 , .001 39.4 61.4 , .001 38.8 67.3 , .001
Socioeconomic
Family income, $ , .001 , .001 , .001
, 15,000 7.1 25.1 8.2 30.7 6.8 23
15,000-30,000 12.3 25 9.4 29.6 13.1 23.3
30,000-50,000 17.1 19.3 18 15.7 16.8 20.6
. 50,000 56.5 25.1 60.5 17.3 55.4 28.1
Not reported 7 5.4 3.9 6.7 7.9 4.9
Insurance
Private 78.9 63.7 , .001 78.7 57.2 , .001 79 66 , .001
Medicaid 6 23.5 , .001 6.9 28.9 , .001 5.8 21.6 , .001
Medicare 35.4 37.4 .51 28.7 32.8 .47 37.2 39.1 .61
Uninsured 2.9 9.7 , .001 2.5 14.8 , .001 3 7.7 .001
Married 71.1 39.4 , .001 73.8 34.2 , .001 70.3 41.4 , .001
Employment .12 .16 .35
Unemployed 53.9 58.7 50.9 61.2 54.7 57.7
Employed 45.4 39.9 47.7 36.8 44.8 41.1
Not reported 0.7 1.4 1.4 2 0.5 1.2
Education , .001 , .001 , .001
HS 49 55.9 39 60.9 51.7 54
College or higher 44.8 30.6 50.4 26.9 43.3 32
Less than HS 6.1 13.5 10.6 12.2 4.9 14
NOTE. Data are the mean with SE or percentage unless otherwise specified.
Abbreviations: COPD, chronic obstructive pulmonary disease; CT, chemotherapy; ET, endocrine therapy; HS, high school; ODX, Oncotype DX (Genomic Health,
Redwood City, CA); PR, progesterone receptor.
*Compared with mastectomy.
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because test results may not influence their treatment decision.33,34
However, among patients with node-positive disease, guidelines
recommend that women receive adjuvant chemotherapy. Therefore,
ODX testing may be most commonly offered to women who are not
ideal candidates for chemotherapy and for whom providers wish to
forgo chemotherapy,34 a situation that potentially accounts for dif-
ferent chemotherapy initiation patterns by node status. Studies to
examine the cost-effectiveness of ODX should be designed to stratify
analyses by nodal status because different patterns of ODX test and
adjuvant chemotherapy use may occur across these strata.
Use of ODX for Patients With Node-Negative Disease
Tumors of medium size (2 to 5 cm), tumors of medium or
higher grade, and those PR positive were associated with an
increased likelihood of ODX testing. This suggests that, among
eligible women, ODX may offer extra information to make
decisions about forgoing chemotherapy, particularly among
women with certain tumor characteristics.24 Perhaps patients with
especially favorable or unfavorable tumor characteristics were
more likely to forgo ODX testing because they and their provider
already had enough information to make an informed decision
about adjuvant chemotherapy without ODX results.
We found differences in neither racial nor SES in ODX test
usage among patients with node-negative disease. Perhaps this is
the result of the wide coverage by private insurers, Medicaid, and
Medicare and the availability of ODX testing for node-negative
breast cancer.6 For eligible women who are uninsured or who lack
adequate coverage for ODX testing, Genomic Health, the maker of
ODX, provides a financial-assistance program.35 This may partially
explain why race and SES were not associated with use of ODX
testing among patients with node-negative disease.
Use of ODX for Patients With Node-Positive Disease
In contrast, among patients with node-positive breast
cancer, black women were significantly less likely to receive
ODX testing than non-black women. In sensitivity analyses, this
trend persisted across the year of breast cancer diagnosis (data
not shown). Unlike testing in node-negative disease, ODX
testing in node-positive disease is not widely covered by insurers
because it is not recommended in guidelines. Because ODX is
not widely covered for women with node-positive disease,
concerns about perceived costs may be a barrier to ODX testing
despite the fact that Genomic Health provides financial assis-
tance. Because SES and race are correlated, perceived costs could
explain potential racial differences in those who receive ODX
testing. This may partially explain the attenuated association of
race with ODX testing in the secondary model that included SES
covariates.
In addition, results from a qualitative study indicated that
North Carolina providers often order ODX testing for patients
with node-positive disease through the ongoing Southwest
Oncology Group RxPONDER trial.34 Low recruitment of black
women into the RxPONDER study may contribute to racial
differences.36,37 Future investigators should test whether an
association exists among race, trial participation, and access to new
genetic technologies.
Current medical guidelines do not recommend ODX testing
in patients with node-positive, early-stage, ER+ breast cancer.
Therefore, lower rates of ODX testing among black women in our
sample reflect their receipt of more guideline-concordant care than
non-black women with node-positive breast cancer. Thus, dif-
ferential receipt of ODX testing does not necessarily reflect a racial
disparity in the quality of care. This paradox illustrates challenges
that will accompany the measurement of disparities in the early
adoption of new genetic technologies into clinical practice.
Pending results from the RxPONDER trial will provide additional
evidence necessary for us to determine whether ODX testing
among patients with node-positive disease is appropriate.34
In the node-positive group, women younger than 50 years
were less likely to receive ODX testing than those older than 50
years. Younger women tend to be healthier and, therefore, often
tolerate chemotherapy better than older women; as a result,
providers may be more likely to start chemotherapy in younger
women, according to guidelines.34,38 An alternative may be that
providers may order ODX testing for older adults to justify their
not giving adjuvant chemotherapy to those who are frail or who
have multiple comorbidities.
Finally, later year of breast cancer diagnosis was correlated
with an increased likelihood of ODX testing in women with
node-positive disease. This is likely a result of the accrual of
evidence for ODX testing among subgroups of these patients
over time. The first major studies whose data suggested the
prognostic validity of ODX testing in node-positive disease were
reported in 2008 for women receiving chemotherapy and
endocrine therapy19 and in 2010 for women receiving endocrine
therapy alone.17,18 In 2010, a randomized study demonstrated
the predictive validity of ODX testing among postmenopausal
women with node-positive breast cancer.16 This may explain
why the year of diagnosis was a strong predictor of the use of
ODX testing in women with node-positive disease. Of note, we
did not see this trend in patients with node-negative disease,
likely because ODX testing had already been added to clinical
guidelines in 2008 for these patients.6 Future researchers should
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ODX Testing by Year of Diagnosis
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Fig 2. Proportion of women with estrogen receptor–positive, human epidermal
growth factor receptor 2–negative, stage I or II disease who underwent Oncotype
DX (ODX; Genomic Health, Redwood City, CA) testing, as reported over time, by
lymph node status with population weightings.
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investigate how racial differences in ODX uptake change as new
evidence for the technology emerges.
Limitations
This study has several limitations. First, we were unable to
account for patient preferences that likely influence ODX testing
and decisions regarding adjuvant chemotherapy. Preferences
related to the treatment of early-stage breast cancer may differ by
race.39 If so, patient preferences may be a mediating variable
between race and ODX testing. Furthermore, we were unable to
assess patient, provider, and organizational attitudes about ODX
testing. Second, use of ODX testing was determined by abstracting
pathology reports. Although it is possible that ODX testing was not
Table 2. Sample Characteristics by ODX Use and Lymph Node Status
Characteristic
Full Sample Node Positive Node Negative
No ODX ODX P No ODX ODX P No ODX ODX P
n 900 568 302 81 598 487
Weighted n 2,734 1,953 734 313 2,001 1640
Tumor
Size, cm .04 .18 , .001
, 2 74 73.6 49.4 61.1 83.1 75.9
2-5 22.9 25.8 48.7 38.1 13.5 23.4
. 5 3 0.7 2 0.8 3.4 0.7
Grade .003 .03 , .001
1 40.7 31 26.6 28.4 45.9 31.5
2 41.3 53.1 43.2 58.4 40.6 52
3 18 16 30.2 13.2 13.5 16.5
PR positive 86.5 91.1 .03 89.7 90.4 .86 85.3 91.2 .01
Treatment
Start ET 87.1 94.1 ,.001 90.6 97 .12 85.9 93.6 , .001
Start adjuvant CT 30.7 26.7 .18 70.4 30.9 , .001 16.1 25.9 , .001
Radiation therapy 69.4 66.4 .38 77.2 61.1 .01 66.5 67.4 .82
Lumpectomy* 38.7 35.4 .43 55.8 38.6 .01 32.4 34.8 .56
Clinical
Age at diagnosis, years 57.6 (10.9) 56.9 (9.9) .28 54.0 (12.0) 58.3 (8.1) .004 58.9 (10.1) 56.6 (10.3) .002
Diagnosis year . .99 .08 .41
2008 10.9 11.5 18.2 6.7 8.2 12.5
2009 19 19.8 17.6 16.1 19.5 20.5
2010 24.6 23.4 20.8 17.6 26 24.5
2011 24.6 24.3 25.7 28.5 24.1 23.5
2012 or 2013 20.9 21.0 17.2 29.8 21.9 18.9
Comorbidities
Diabetes 15.5 10.6 .03 15.7 10.6 .39 15.4 10.6 .06
COPD 4.9 1.8 .01 5.3 0 .08 4.8 2.1 .05
Obesity 13 12.6 .86 14.3 6.5 .12 12.5 13.8 .59
Heart disease 8.9 3.9 .005 8.5 4.8 .4 9 3.7 .008
Hypertension 45.3 40.8 .19 41.8 49.3 .28 46.7 39.2 .07
Socioeconomic
Family income, $ , .001 .002 .006
, 15,000 12.2 7.2 15.9 6.1 10.9 7.4
15,000-30,000 15.6 12.9 14.2 12.2 16.1 13
30,000-50,000 17.4 17.6 21 9.4 16 19.2
. 50,000 46.2 58.1 43.2 70.7 47.3 55.7
Not reported 8.6 4.1 5.7 1.7 9.7 4.6
Insurance
Private 74.6 79.1 .13 72.8 79 .39 75.3 79.1 .26
Medicaid 10.3 6.7 .03 11.9 9.1 .55 9.7 6.3 .04
Medicare 37.3 33.5 .24 29 30.5 .82 40.3 34.1 .09
Uninsured 4.7 3 .06 6.1 2.7 .08 4.2 3.1 .3
Married 62.7 70 .02 62.1 73.6 .06 62.8 69.3 .06
Employment Status .11 .35 .009
Unemployed 57.4 50.9 53.1 53 59 50.5
Employed 41.7 48.5 46.1 43.8 40 49.3
Not reported 0.9 0.7 0.8 3.2 1 0.2
Education .07 .56 .09
HS 51 49.1 41.8 47.9 54.4 49.3
College or higher 40.3 45.4 46.1 44.1 38.2 45.6
Less than HS 8.7 5.6 12.2 8 7.4 5.1
NOTE. Data are the mean with SE or percentage unless otherwise specified.
Abbreviations: COPD, chronic obstructive pulmonary disease; CT, chemotherapy; ET, endocrine therapy; HS, high school; ODX, Oncotype DX (Genomic Health,
Redwood City, CA); PR, progesterone receptor.
*Compared with mastectomy.
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added to medical and pathology records, our rates of ODX
uptake were similar to those reported in other studies.22,23 Third,
our study was powered to reveal 10% unadjusted racial differ-
ences; however, when we included covariates, our secondary
models were underpowered. Because of power limitations, we
were unable to examine racial differences in subsequent che-
motherapy uptake by lymph node status. However, data from
two studies suggest that racial disparities in use of adjuvant
chemotherapy do not occur among all women, that is, those with
node-positive and those with node-negative disease, who receive
ODX testing.22,40 Also, our study lacked power to examine racial
differences in uptake of ODX testing by node status over time
beyond the exploratory analyses. Of note, with its oversampling
of black women, CBCS phase III presented the best opportunity
currently available to examine racial disparities surrounding
ODX test uptake. Fourth, our models did not include organ-
izational or provider characteristics that may have influence
ODX test use. Organizational factors, such as being examined at
a municipal versus tertiary medical centers23 or at community
cancer centers versus a comprehensive cancer center,25 may
decrease the likelihood of ODX testing. Planned data linkages
will facilitate the exploration of multilevel factors in the future.
Fifth, we were unable to disaggregate race by ethnicity or country
of origin. Finally, our inclusion of SES required us to redefine
family income to include a not-reported category. This repre-
sents a challenge in the measurement of the independent effects
of SES because nonrandom underreporting is common.41In
conclusion, this study contributes to our understanding of racial
variation in ODX test uptake, particularly by revealing differ-
ences across lymph node status. Racial disparities were not
observed among women with node-negative disease for whom
ODX testing is guideline recommended and widely covered by
insurance. This is heartening because genetic technologies are
being incorporated into clinical guidelines for cancer care. In
the converse, the observed racial difference in patients with
node-positive disease suggests that newer, non–guideline-
recommended applications of genetic technologies may be
used less by those from racial minority groups than by others.
This may be the result of disparities in clinical trial participation,
less insurance coverage, or unexplained provider and organ-
izational differences in the use of genetic technology where racial
minority groups access care. Future investigators should
Table 3. Modified Poisson Regression Results for ODX Test Use for Patients With Node-Negative Breast Cancer
Characteristic
Primary Model Secondary Model
RR 95% CI P RR 95% CI P
Black v non-black* 0.91 0.76 to 1.094 .33 0.95 0.78 to 1.15 .58
Tumor size v , 2 cm, cm
2-5 1.30 1.083 to 1.56 .005 1.31 1.10 to 1.56 .003
. 5 0.31 0.089 to 1.045 .059 0.31 0.091 to 1.019 .054
Grade v 1
2 1.41 1.16 to 1.72 .001 1.41 1.15 to 1.72 .001
3 1.42 1.098 to 1.83 .007 1.45 1.13 to 1.86 .003
PR positive v negative 1.48 1.085 to 2.029 .014 1.50 1.099 to 2.051 .011
Mastectomy v lumpectomy 1.031 0.86 to 1.23 .74 1.05 0.88 to 1.25 .58
No. of comorbidities 0.91 0.83 to 1.011 .080 0.95 0.86 to 1.060 .38
Age at diagnosis , 50 v . 50 years 1.13 0.95 to 1.33 .16 1.074 0.90 to 1.28 .42
Diagnosis year v 2008
2009 0.86 0.66 to 1.12 .26 0.84 0.65 to 1.10 .22
2010 0.84 0.66 to 1.072 .16 0.78 0.60 to 1.00 .052
2011 0.85 0.66 to 1.10 .23 0.8 0.62 to 1.038 .093
2012 or 2013 0.79 0.58 to 1.074 .13 0.74 0.54 to 1.011 .058
Family income v , $15,000, $
15,000-30,000 0.97 0.66 to 1.43 .89
30,000-50,000 1.12 0.77 to 1.62 .56
. 50,000 1.017 0.68 to 1.52 .94
Not reported 0.64 0.39 to 1.069 .088
Uninsured v insured 0.84 0.55 to 1.28 .42
Married v unmarried 1.11 0.91 to 1.37 .30
Employment v unemployed
Employed 1.068 0.89 to 1.29 .48
Not reported 0.46 0.91 to 2.13 .32
Education v HS or v HS or higher
College or higher 1.082 0.92 to 1.27 .33
Less than HS 0.87 0.56 to 1.35 .53
Constant† 0.30 0.19 to 0.47 ,.001 0.26 0.15 to 0.45 , .001
NOTE. N = 1,049. The number of primary sampling units (ie, provider) used to account for provider-level clustering was 455. Population-weighted
sample size = 3,641. Primary model covariates were tumor size, tumor grade, PR status, surgery type, number of comorbidities, age at diagnosis, and
year of diagnosis. Additional secondary model covariates were family income, health insurance status, marital status, employment status, and education
level.
Abbreviations: HS, high school; ODX, Oncotype DX (Genomic Health, Redwood City, CA); PR, progesterone receptor; RR, risk ratio.
*Results for the crude model were RR, 0.90; 95% CI, 0.77 to 1.067; P = .23.
†Results for the crude model were RR, 0.46; 95% CI, 0.41 to 0.51; P = , .001.
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explicitly examine the association of these factors with ODX
testing.
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GLOSSARY TERMS
Oncotype DX classifier: a classifier used to estimate risk
of recurrence for patients with node-negative estrogen
receptor–positive primary breast cancer receiving tamoxifen.
Components of this classifier are expression levels based on
reverse transcription polymerase chain reaction optimized
for use with paraffin-embedded, formalin-fixed tissue of selected
genes that were initially identified as prognostic based on
published microarray studies. The completely specified classifier
was externally validated based on archived specimens from
independent studies.
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